China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), a 60.25%-owned subsidiary of China Resources Pharmaceutical Group Limited (CR Pharma), released unaudited results for the three months ended 31 March 2026.

Revenue fell 8.84% year on year to RMB 2.81 billion, while net profit slipped 4.08% to RMB 0.50 billion.

Operating cash generation strengthened: net cash inflow rose 141.90% to RMB 0.66 billion. However, end-period cash and cash equivalents contracted 17.50% to RMB 2.57 billion.

Total assets expanded 5.87% versus 31 December 2025 to RMB 18.01 billion. Total liabilities increased 11.00% to RMB 5.00 billion, lifting the debt ratio to 27.79%. Owner’s equity improved 4.02% to RMB 13.00 billion.

The figures are prepared under PRC GAAP and remain unaudited; they represent CR Double-Crane only and do not reflect the consolidated position of CR Pharma. Shareholders should exercise caution when interpreting these standalone results.